Lancet Respiratory Medicine

Article	Citations
Pulmonary and cardiac pathology in African American patients with COVID-19: an autopsy series from New Orleans	922
Pulmonary fibrosis and COVID-19: the potential role for antifibrotic therapy	757
Cytokine elevation in severe and critical COVID-19: a rapid systematic review, meta-analysis, and comparison with other inflammatory syndromes	647
Case characteristics, resource use, and outcomes of 10 021 patients with COVID-19 admitted to 920 German hospitals: an observational study	595
Pathophysiology of COVID-19-associated acute respiratory distress syndrome: a multicentre prospective observational study	486
COVID-19 and the impact of social determinants of health	484
Efficacy and safety of baricitinib for the treatment of hospitalised adults with COVID-19 (COV-BARRIER): a randomised, double-blind, parallel-group, placebo-controlled phase 3 trial	482
3-month, 6-month, 9-month, and 12-month respiratory outcomes in patients following COVID-19-related hospitalisation: a prospective study	456
Global, regional, and national prevalence of, and risk factors for, chronic obstructive pulmonary disease (COPD) in 2019: a systematic review and modelling analysis	453
Management of acute kidney injury in patients with COVID-19	437
Particle sizes of infectious aerosols: implications for infection control	423
SARS-CoV-2 viral load predicts COVID-19 mortality	412
Tropism, replication competence, and innate immune responses of the coronavirus SARS-CoV-2 in human respiratory tract and conjunctiva: an analysis in ex-vivo and in-vitro cultures	402
Comparison of the characteristics, morbidity, and mortality of COVID-19 and seasonal influenza: a nationwide, population-based retrospective cohort study	398
Physical, cognitive, and mental health impacts of COVID-19 after hospitalisation (PHOSP-COVID): a UK multicentre, prospective cohort study	397
Tocilizumab in systemic sclerosis: a randomised, double-blind, placebo-controlled, phase 3 trial	385
The COVID-19 puzzle: deciphering pathophysiology and phenotypes of a new disease entity	368
Feasibility and physiological effects of prone positioning in non-intubated patients with acute respiratory failure due to COVID-19 (PRON-COVID): a prospective cohort study	364
Pulmonary fibrosis secondary to COVID-19: a call to arms?	356
COVID-19-associated acute respiratory distress syndrome: is a different approach to management warranted?	355
Safety and efficacy of inhaled nebulised interferon beta-1a (SNG001) for treatment of SARS-CoV-2 infection: a randomised, double-blind, placebo-controlled, phase 2 trial	339
Extracorporeal membrane oxygenation for severe acute respiratory distress syndrome associated with COVID-19: a retrospective cohort study	335
Human recombinant soluble ACE2 in severe COVID-19	331
Prevalence and risk factors for delirium in critically ill patients with COVID-19 (COVID-D): a multicentre cohort study	321
NICE guideline on long COVID	319

Interstitial lung abnormalities detected incidentally on CT: a Position Paper from the Fleischner Society	314
Health outcomes in people 2 years after surviving hospitalisation with COVID-19: a longitudinal cohort study	302
Characterisation of the first 250 000 hospital admissions for COVID-19 in Brazil: a retrospective analysis of nationwide data	281
BNT162b2 COVID-19 vaccine and correlates of humoral immune responses and dynamics: a prospective, single-centre, longitudinal cohort study in health-care workers	280
Small droplet aerosols in poorly ventilated spaces and SARS-CoV-2 transmission	280
New variant of SARS-CoV-2 in UK causes surge of COVID-19	279
Pembrolizumab with or without radiotherapy for metastatic non-small-cell lung cancer: a pooled analysis of two randomised trials	278
Tracheostomy in the COVID-19 era: global and multidisciplinary guidance	277
Pirfenidone in patients with progressive fibrotic interstitial lung diseases other than idiopathic pulmonary fibrosis (RELIEF): a double-blind, randomised, placebo-controlled, phase 2b trial	275
Inhaled budesonide in the treatment of early COVID-19 (STOIC): a phase 2, open-label, randomised controlled trial	275
Mepolizumab for chronic rhinosinusitis with nasal polyps (SYNAPSE): a randomised, double-blind, placebo-controlled, phase 3 trial	275
Camrelizumab plus carboplatin and pemetrexed versus chemotherapy alone in chemotherapy-naive patients with advanced non-squamous non-small-cell lung cancer (CameL): a randomised, open-label, multicent	275
False-positive COVID-19 results: hidden problems and costs	255
Safety, reactogenicity, and immunogenicity of homologous and heterologous prime-boost immunisation with ChAdOx1 nCoV-19 and BNT162b2: a prospective cohort study	246
COVID-19: a heavy toll on health-care workers	243
Awake prone positioning for COVID-19 acute hypoxaemic respiratory failure: a randomised, controlled, multinational, open-label meta-trial	235
Omicron variant and booster COVID-19 vaccines	221
Clinical characteristics with inflammation profiling of long COVID and association with 1-year recovery following hospitalisation in the UK: a prospective observational study	213
Colchicine for community-treated patients with COVID-19 (COLCORONA): a phase 3, randomised, double-blinded, adaptive, placebo-controlled, multicentre trial	207
Progressive fibrosing interstitial lung disease: clinical uncertainties, consensus recommendations, and research priorities	207
Risk of COVID-19-related death among patients with chronic obstructive pulmonary disease or asthma prescribed inhaled corticosteroids: an observational cohort study using the OpenSAFELY platform	206
Effect of anakinra versus usual care in adults in hospital with COVID-19 and mild-to-moderate pneumonia (CORIMUNO-ANA-1): a randomised controlled trial	205
Confronting COVID-19-associated cough and the post-COVID syndrome: role of viral neurotropism, neuroinflammation, and neuroimmune responses	198
Sarilumab in patients admitted to hospital with severe or critical COVID-19: a randomised, double-blind, placebo-controlled, phase 3 trial	190
Continuation versus discontinuation of renin–angiotensin system inhibitors in patients admitted to hospital with COVID-19: a prospective, randomised, open-label trial	187
Peginterferon lambda for the treatment of outpatients with COVID-19: a phase 2, placebo-controlled randomised trial	184
Association between pre-existing respiratory disease and its treatment, and severe COVID-19: a population cohort study	182
Ventilation management and clinical outcomes in invasively ventilated patients with COVID-19 (PRoVENT-COVID): a national, multicentre, observational cohort study	182
Tocilizumab plus standard care versus standard care in patients in India with moderate to severe COVID-19-associated cytokine release syndrome (COVINTOC): an open-label, multicentre, randomised, contr	172
Prevalence of phenotypes of acute respiratory distress syndrome in critically ill patients with COVID-19: a prospective observational study	171
Early outcomes after lung transplantation for severe COVID-19: a series of the first consecutive cases from four countries	170
Fungal infections in mechanically ventilated patients with COVID-19 during the first wave: the French multicentre MYCOVID study	168
Tepotinib plus gefitinib in patients with EGFR-mutant non-small-cell lung cancer with MET overexpression or MET amplification and acquired resistance to previous EGFR inhibitor (INSIGHT study): an ope	166
Extracorporeal membrane oxygenation network organisation and clinical outcomes during the COVID-19 pandemic in Greater Paris, France: a multicentre cohort study	158
Rising incidence of mucormycosis in patients with COVID-19: another challenge for India amidst the second wave?	157
Effect of tezepelumab on airway inflammatory cells, remodelling, and hyperresponsiveness in patients with moderate-to-severe uncontrolled asthma (CASCADE): a double-blind, randomised, placebo-controll	152
Chronic obstructive pulmonary disease in never-smokers: risk factors, pathogenesis, and implications for prevention and treatment	150
SARS-CoV-2 evolution and vaccines: cause for concern?	147
Development and validation of the ISARIC 4C Deterioration model for adults hospitalised with COVID-19: a prospective cohort study	147
Efficacy and safety of intramuscular administration of tixagevimab–cilgavimab for early outpatient treatment of COVID-19 (TACKLE): a phase 3, randomised, double-blind, placebo-controlled trial	146
Gefapixant, a P2X3 receptor antagonist, for the treatment of refractory or unexplained chronic cough: a randomised, double-blind, controlled, parallel-group, phase 2b trial	146
Decreasing antibiotic use, the gut microbiota, and asthma incidence in children: evidence from population-based and prospective cohort studies	143
Efficacy and safety of once-daily single-inhaler triple therapy (FF/UMEC/VI) versus FF/VI in patients with inadequately controlled asthma (CAPTAIN): a double-blind, randomised, phase 3A trial	140
Pulmonary vascular resistance and clinical outcomes in patients with pulmonary hypertension: a retrospective cohort study	138
Cytokine adsorption in patients with severe COVID-19 pneumonia requiring extracorporeal membrane oxygenation (CYCOV): a single centre, open-label, randomised, controlled trial	132
SARS-CoV-2 seropositivity and subsequent infection risk in healthy young adults: a prospective cohort study	130
Interleukin-6: obstacles to targeting a complex cytokine in critical illness	128
Efficacy and safety of nintedanib in patients with systemic sclerosis-associated interstitial lung disease treated with mycophenolate: a subgroup analysis of the SENSCIS trial	128
Tobacco smoking and COVID-19 infection	128
Efficacy and safety of baricitinib plus standard of care for the treatment of critically ill hospitalised adults with COVID-19 on invasive mechanical ventilation or extracorporeal membrane oxygenation	126

Efficacy of interferon beta-1a plus remdesivir compared with remdesivir alone in hospitalised adults with COVID-19: a double-blind, randomised, placebo-controlled, phase 3 trial	124
Risk of adverse outcomes in patients with underlying respiratory conditions admitted to hospital with COVID-19: a national, multicentre prospective cohort study using the ISARIC WHO Clinical Character	122
Once-daily savolitinib in Chinese patients with pulmonary sarcomatoid carcinomas and other non-small-cell lung cancers harbouring MET exon 14 skipping alterations: a multicentre, single-arm, open-labe	120
Beyond the clot: perfusion imaging of the pulmonary vasculature after COVID-19	120
Neutrophil extracellular traps, disease severity, and antibiotic response in bronchiectasis: an international, observational, multicohort study	119
COVID-19 hospital admissions and deaths after BNT162b2 and ChAdOx1 nCoV-19 vaccinations in 2·57 million people in Scotland (EAVE II): a prospective cohort study	118
Long-term safety and efficacy of dupilumab in patients with moderate-to-severe asthma (TRAVERSE): an open-label extension study	118
Addressing the post-acute sequelae of SARS-CoV-2 infection: a multidisciplinary model of care	116
Pathogenesis of chronic obstructive pulmonary disease: understanding the contributions of gene–environment interactions across the lifespan	115
Does infection with or vaccination against SARS-CoV-2 lead to lasting immunity?	115
The intersecting pandemics of tuberculosis and COVID-19: population-level and patient-level impact, clinical presentation, and corrective interventions	113
A core outcome set for post-COVID-19 condition in adults for use in clinical practice and research: an international Delphi consensus study	111
Time-varying intensity of mechanical ventilation and mortality in patients with acute respiratory failure: a registry-based, prospective cohort study	110
Age-sex specific pulmonary embolism-related mortality in the USA and Canada, 2000–18: an analysis of the WHO Mortality Database and of the CDC Multiple Cause of Death database	110
Durability of BNT162b2 vaccine against hospital and emergency department admissions due to the omicron and delta variants in a large health system in the USA: a test-negative case–control study	109
Colchicine in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial	108
Onset of effect and impact on health-related quality of life, exacerbation rate, lung function, and nasal polyposis symptoms for patients with severe eosinophilic asthma treated with benralizumab (AND	107
Pembrolizumab in patients with non-small-cell lung cancer of performance status 2 (PePS2): a single arm, phase 2 trial	106
COVID-19 transmission—up in the air	106
Myopericarditis following COVID-19 vaccination and non-COVID-19 vaccination: a systematic review and meta-analysis	106
Therapeutic blockade of granulocyte macrophage colony-stimulating factor in COVID-19-associated hyperinflammation: challenges and opportunities	105
Immunotherapies for COVID-19: lessons learned from sepsis	105
Safety and immunogenicity of CpG 1018 and aluminium hydroxide-adjuvanted SARS-CoV-2 S-2P protein vaccine MVC-COV1901: interim results of a large-scale, double-blind, randomised, placebo-controlled pha	104
Implications of the second wave of COVID-19 in India	103
Patient factors and temporal trends associated with COVID-19 in-hospital mortality in England: an observational study using administrative data	102
The Russian vaccine for COVID-19	102
Lung transplantation for COVID-19-associated acute respiratory distress syndrome in a PCR-positive patient	101
Long-term effectiveness of COVID-19 vaccines against infections, hospitalisations, and mortality in adults: findings from a rapid living systematic evidence synthesis and meta-analysis up to December,	101
Once-daily, single-inhaler mometasone–indacaterol–glycopyrronium versus mometasone–indacaterol or twice-daily fluticasone–salmeterol in patients with inadequately controlled asthma (IRIDIUM): a random	100
Telomere length and risk of idiopathic pulmonary fibrosis and chronic obstructive pulmonary disease: a mendelian randomisation study	99
Global, regional, and national burden of respiratory tract cancers and associated risk factors from 1990 to 2019: a systematic analysis for the Global Burden of Disease Study 2019	98
Clinical impact of molecular point-of-care testing for suspected COVID-19 in hospital (COV-19POC): a prospective, interventional, non-randomised, controlled study	98
The genetics of asthma and the promise of genomics-guided drug target discovery	97
Point-of-care serological assays for delayed SARS-CoV-2 case identification among health-care workers in the UK: a prospective multicentre cohort study	97
GOLD COPD report: 2023 update	97
Dexamethasone in hospitalised patients with COVID-19: addressing uncertainties	96
Major differences in ICU admissions during the first and second COVID-19 wave in Germany	96
Physical distancing in schools for SARS-CoV-2 and the resurgence of rhinovirus	95
Advancing precision medicine for acute respiratory distress syndrome	94
Safety and immunogenicity of heterologous boost immunisation with an orally administered aerosolised Ad5-nCoV after two-dose priming with an inactivated SARS-CoV-2 vaccine in Chinese adults: a randomi	93
Icotinib versus chemotherapy as adjuvant treatment for stage II–IIIA EGFR-mutant non-small-cell lung cancer (EVIDENCE): a randomised, open-label, phase 3 trial	93
Effect of anti-interleukin drugs in patients with COVID-19 and signs of cytokine release syndrome (COV-AID): a factorial, randomised, controlled trial	92
Rituximab versus intravenous cyclophosphamide in patients with connective tissue disease-associated interstitial lung disease in the UK (RECITAL): a double-blind, double-dummy, randomised, controlled,	91
Switching to riociguat versus maintenance therapy with phosphodiesterase-5 inhibitors in patients with pulmonary arterial hypertension (REPLACE): a multicentre, open-label, randomised controlled trial	90
Criteria and definitions for the radiological and clinical diagnosis of bronchiectasis in adults for use in clinical trials: international consensus recommendations	90
When to consider lung transplantation for COVID-19	90
COVID-19 interstitial pneumonia: monitoring the clinical course in survivors	89
The long-term sequelae of COVID-19: an international consensus on research priorities for patients with pre-existing and new-onset airways disease	87
Oral corticosteroid elimination via a personalised reduction algorithm in adults with severe, eosinophilic asthma treated with benralizumab (PONENTE): a multicentre, open-label, single-arm study	86
Airway mucin MUC5AC and MUC5B concentrations and the initiation and progression of chronic obstructive pulmonary disease: an analysis of the SPIROMICS cohort	86
One-off low-dose CT for lung cancer screening in China: a multicentre, population-based, prospective cohort study	86
Balloon pulmonary angioplasty versus riociguat for the treatment of inoperable chronic thromboembolic pulmonary hypertension (RACE): a multicentre, phase 3, open-label, randomised controlled trial and	86
Interleukin-6 receptor blockade in patients with COVID-19: placing clinical trials into context	85
Imatinib in patients with severe COVID-19: a randomised, double-blind, placebo-controlled, clinical trial	84
Advances in understanding and reducing the burden of severe asthma in children	84
Composite type-2 biomarker strategy versus a symptom–risk-based algorithm to adjust corticosteroid dose in patients with severe asthma: a multicentre, single-blind, parallel group, randomised controll	84
Predictive value of blood eosinophils and exhaled nitric oxide in adults with mild asthma: a prespecified subgroup analysis of an open-label, parallel-group, randomised controlled trial	83
Saliva as a gold-standard sample for SARS-CoV-2 detection	83
The Berlin definition of acute respiratory distress syndrome: should patients receiving high-flow nasal oxygen be included?	83
Safety and efficacy of itepekimab in patients with moderate-to-severe COPD: a genetic association study and randomised, double-blind, phase 2a trial	83
The sputum microbiome and clinical outcomes in patients with bronchiectasis: a prospective observational study	83
Efficacy and safety of sildenafil added to pirfenidone in patients with advanced idiopathic pulmonary fibrosis and risk of pulmonary hypertension: a double-blind, randomised, placebo-controlled, phase	83
Safety, immunogenicity, and efficacy of a COVID-19 vaccine (NVX-CoV2373) co-administered with seasonal influenza vaccines: an exploratory substudy of a randomised, observer-blinded, placebo-controlled	83
Lymphangioleiomyomatosis: pathogenesis, clinical features, diagnosis, and management	82
Allocating scarce intensive care resources during the COVID-19 pandemic: practical challenges to theoretical frameworks	81
Circulating tumour cells as a potential biomarker for lung cancer screening: a prospective cohort study	81
Lifting of COVID-19 restrictions in the UK and the Delta variant	81
Clinical characteristics and outcomes of invasively ventilated patients with COVID-19 in Argentina (SATICOVID): a prospective, multicentre cohort study	81
The global prevalence and ethnic heterogeneity of primary ciliary dyskinesia gene variants: a genetic database analysis	80
Prevalence and risk factors of small airway dysfunction, and association with smoking, in China: findings from a national cross-sectional study	79
Safety and immunogenicity of a live-attenuated influenza virus vector-based intranasal SARS-CoV-2 vaccine in adults: randomised, double-blind, placebo-controlled, phase 1 and 2 trials	77
Awake prone positioning for non-intubated patients with COVID-19-related acute hypoxaemic respiratory failure: a systematic review and meta-analysis	76
The Acute COPD Exacerbation Prediction Tool (ACCEPT): a modelling study	76
Corticosteroids for COVID-19: the search for an optimum duration of therapy	75
Changes in in-hospital mortality in the first wave of COVID-19: a multicentre prospective observational cohort study using the WHO Clinical Characterisation Protocol UK	75
COVID-19 among people experiencing homelessness in England: a modelling study	75
Baseline FeNO as a prognostic biomarker for subsequent severe asthma exacerbations in patients with uncontrolled, moderate-to-severe asthma receiving placebo in the LIBERTY ASTHMA QUEST study: a post-	75
Chronic obstructive pulmonary disease and related phenotypes: polygenic risk scores in population-based and case-control cohorts	74
Nebulised ALX-0171 for respiratory syncytial virus lower respiratory tract infection in hospitalised children: a double-blind, randomised, placebo-controlled, phase 2b trial	73
Prevalence, risk factors, and clinical implications of preserved ratio impaired spirometry: a UK Biobank cohort analysis	73

Longitudinal respiratory subphenotypes in patients with COVID-19-related acute respiratory distress syndrome: results from three observational cohorts	73
Efficacy and safety of elexacaftor plus tezacaftor plus ivacaftor versus tezacaftor plus ivacaftor in people with cystic fibrosis homozygous for F508del-CFTR: a 24-week, multicentre, randomised, doubl	73
The burden of respiratory syncytial virus in healthy term-born infants in Europe: a prospective birth cohort study	72
Variations in end-of-life practices in intensive care units worldwide (Ethicus-2): a prospective observational study	72
Long COVID: aiming for a consensus	72
Bronchiectasis in Europe: data on disease characteristics from the European Bronchiectasis registry (EMBARC)	71
Validation and utility of ARDS subphenotypes identified by machine-learning models using clinical data: an observational, multicohort, retrospective analysis	71
Phenotyping of idiopathic pulmonary arterial hypertension: a registry analysis	71
Rucaparib in patients with BAP1-deficient or BRCA1-deficient mesothelioma (MiST1): an open-label, single-arm, phase 2a clinical trial	71
Discontinuation versus continuation of renin-angiotensin-system inhibitors in COVID-19 (ACEI-COVID): a prospective, parallel group, randomised, controlled, open-label trial	71
Furmonertinib (AST2818) versus gefitinib as first-line therapy for Chinese patients with locally advanced or metastatic EGFR mutation-positive non-small-cell lung cancer (FURLONG): a multicentre, doub	69
Effectiveness of fevipiprant in reducing exacerbations in patients with severe asthma (LUSTER-1 and LUSTER-2): two phase 3 randomised controlled trials	69
Safety, tolerability, and efficacy of pirfenidone in patients with rheumatoid arthritis-associated interstitial lung disease: a randomised, double-blind, placebo-controlled, phase 2 study	69
Inhaled treprostinil and forced vital capacity in patients with interstitial lung disease and associated pulmonary hypertension: a post-hoc analysis of the INCREASE study	68
Cyclophosphamide added to glucocorticoids in acute exacerbation of idiopathic pulmonary fibrosis (EXAFIP): a randomised, double-blind, placebo-controlled, phase 3 trial	68
Onset and window of SARS-CoV-2 infectiousness and temporal correlation with symptom onset: a prospective, longitudinal, community cohort study	68
Efficacy, safety, and genetic analysis of furmonertinib (AST2818) in patients with EGFR T790M mutated non-small-cell lung cancer: a phase 2b, multicentre, single-arm, open-label study	68
Assessing the strength of evidence for a causal effect of respiratory syncytial virus lower respiratory tract infections on subsequent wheezing illness: a systematic review and meta-analysis	66
Early diagnosis of fibrotic interstitial lung disease: challenges and opportunities	66
Safety and effectiveness of bronchial thermoplasty after 10 years in patients with persistent asthma (BT10+): a follow-up of three randomised controlled trials	65
Evaluation of the oral corticosteroid-sparing effect of tezepelumab in adults with oral corticosteroid-dependent asthma (SOURCE): a randomised, placebo-controlled, phase 3 study	64
Anti-C5a antibody (vilobelimab) therapy for critically ill, invasively mechanically ventilated patients with COVID-19 (PANAMO): a multicentre, double-blind, randomised, placebo-controlled, phase 3 tri	64
Adjunctive host-directed therapies for pulmonary tuberculosis: a prospective, open-label, phase 2, randomised controlled trial	64
Efficacy and safety of first-line lorlatinib versus crizotinib in patients with advanced, ALK-positive non-small-cell lung cancer: updated analysis of data from the phase 3, randomised, open-label CRO	64
National burden estimates of hospitalisations for acute lower respiratory infections due to respiratory syncytial virus in young children in 2019 among 58 countries: a modelling study	63
Safety and immunogenicity of a high-dose quadrivalent influenza vaccine administered concomitantly with a third dose of the mRNA-1273 SARS-CoV-2 vaccine in adults aged ≥65 years: a phase 2, randomised	63
Azithromycin versus standard care in patients with mild-to-moderate COVID-19 (ATOMIC2): an open-label, randomised trial	63
Baricitinib versus dexamethasone for adults hospitalised with COVID-19 (ACTT-4): a randomised, double-blind, double placebo-controlled trial	63
High-titre methylene blue-treated convalescent plasma as an early treatment for outpatients with COVID-19: a randomised, placebo-controlled trial	61
Use of facemasks during the COVID-19 pandemic	61
Bevacizumab plus erlotinib versus erlotinib alone in Japanese patients with advanced, metastatic, EGFR-mutant non-small-cell lung cancer (NEJ026): overall survival analysis of an open-label, randomise	61
Tixagevimab–cilgavimab for treatment of patients hospitalised with COVID-19: a randomised, double-blind, phase 3 trial	60
Efficacy and safety of landiolol, an ultra-short-acting β1-selective antagonist, for treatment of sepsis-related tachyarrhythmia (J-Land 3S): a multicentre, open-label, randomised controlled trial	59
Long-term immunogenicity of BNT162b2 vaccination in older people and younger health-care workers	59
Segmentectomy for ground-glass-dominant lung cancer with a tumour diameter of 3 cm or less including ground-glass opacity (JCOG1211): a multicentre, single-arm, confirmatory, phase 3 trial	58
Dynamic zero COVID policy in the fight against COVID	58
Clinical trials in critical care: can a Bayesian approach enhance clinical and scientific decision making?	57
COVID-19-associated Aspergillus tracheobronchitis: the interplay between viral tropism, host defence, and fungal invasion	57
Early humoral response among lung transplant recipients vaccinated with BNT162b2 vaccine	57
Lung microbiota predict chronic rejection in healthy lung transplant recipients: a prospective cohort study	57
The inflammatory profile of exacerbations in patients with severe refractory eosinophilic asthma receiving mepolizumab (the MEX study): a prospective observational study	56
Inhaled isoflurane via the anaesthetic conserving device versus propofol for sedation of invasively ventilated patients in intensive care units in Germany and Slovenia: an open-label, phase 3, randomi	55
Identification of phenotypes in paediatric patients with acute respiratory distress syndrome: a latent class analysis	55
COVID-19 hospital admissions: Brazil's first and second waves compared	55
Effect of a 2-week interruption in methotrexate treatment versus continued treatment on COVID-19 booster vaccine immunity in adults with inflammatory conditions (VROOM study): a randomised, open label	55
Delayed-onset myocarditis following COVID-19	54
Fast multiplex bacterial PCR of bronchoalveolar lavage for antibiotic stewardship in hospitalised patients with pneumonia at risk of Gram-negative bacterial infection (Flagship II): a multicentre, ran	53
Effects of remdesivir in patients hospitalised with COVID-19: a systematic review and individual patient data meta-analysis of randomised controlled trials	52
A new paradigm is needed to explain long COVID	52
Doxycycline for community treatment of suspected COVID-19 in people at high risk of adverse outcomes in the UK (PRINCIPLE): a randomised, controlled, open-label, adaptive platform trial	52
Low versus standard calorie and protein feeding in ventilated adults with shock: a randomised, controlled, multicentre, open-label, parallel-group trial (NUTRIREA-3)	52
Lung function testing in the COVID-19 endemic	51
Extracorporeal membrane oxygenation for COVID-19 during first and second waves	51
Imaging research in fibrotic lung disease; applying deep learning to unsolved problems	51
Effect of early mobilisation on long-term cognitive impairment in critical illness in the USA: a randomised controlled trial	50
Inhaled corticosteroids in virus pandemics: a treatment for COVID-19?	50
Safety and immunogenicity of the adjunct therapeutic vaccine ID93 + GLA-SE in adults who have completed treatment for tuberculosis: a randomised, double-blind, placebo-controlled, phase 2a trial	50
Risk of COVID-19 hospital admission among children aged 5–17 years with asthma in Scotland: a national incident cohort study	50
Genetics of chronic obstructive pulmonary disease: understanding the pathobiology and heterogeneity of a complex disorder	49
Could a good night's sleep improve COVID-19 vaccine efficacy?	49
Lifetime spirometry patterns of obstruction and restriction, and their risk factors and outcomes: a prospective cohort study	49
Aerosol generating procedures: are they of relevance for transmission of SARS-CoV-2?	48
Lung epithelial and myeloid innate immunity in influenza-associated or COVID-19-associated pulmonary aspergillosis: an observational study	48
Discontinuation versus continuation of hypertonic saline or dornase alfa in modulator treated people with cystic fibrosis (SIMPLIFY): results from two parallel, multicentre, open-label, randomised, co	47
Comparative vaccine effectiveness against severe COVID-19 over time in US hospital administrative data: a case-control study	46
GOLD report: 2022 update	46
Weaning from mechanical ventilation in intensive care units across 50 countries (WEAN SAFE): a multicentre, prospective, observational cohort study	46
Repurposing drugs for treatment of COVID-19	45
Effect of a single day of increased as-needed budesonide–formoterol use on short-term risk of severe exacerbations in patients with mild asthma: a post-hoc analysis of the SYGMA 1 study	45
Post-acute sequelae of COVID-19: understanding and addressing the burden of multisystem manifestations	45
Lenzilumab in hospitalised patients with COVID-19 pneumonia (LIVE-AIR): a phase 3, randomised, placebo-controlled trial	44
Asthma in children during the COVID-19 pandemic: lessons from lockdown and future directions for management	44
Small airway loss in the physiologically ageing lung: a cross-sectional study in unused donor lungs	44
Trajectories of asthma and allergies from 7 years to 53 years and associations with lung function and extrapulmonary comorbidity profiles: a prospective cohort study	44
Association between very to moderate preterm births, lung function deficits, and COPD at age 53 years: analysis of a prospective cohort study	44
An online breathing and wellbeing programme (ENO Breathe) for people with persistent symptoms following COVID-19: a parallel-group, single-blind, randomised controlled trial	43
Assessing the importance of interleukin-6 in COVID-19	43
Long-term safety and efficacy of tezepelumab in people with severe, uncontrolled asthma (DESTINATION): a randomised, placebo-controlled extension study	43
Efficacy and safety of pembrolizumab in patients with advanced mesothelioma in the open-label, single-arm, phase 2 KEYNOTE-158 study	43
The role of small airway dysfunction in asthma control and exacerbations: a longitudinal, observational analysis using data from the ATLANTIS study	43
The role of antiviral treatment in the COVID-19 pandemic	43
Non-invasive respiratory support strategies in COVID-19	42
Balloon pulmonary angioplasty versus riociguat in inoperable chronic thromboembolic pulmonary hypertension (MR BPA): an open-label, randomised controlled trial	42
A tricompartmental model of lung oxygenation disruption to explain pulmonary and systemic pathology in severe COVID-19	42
α1-Antitrypsin deficiency and the risk of COVID-19: an urgent call to action	42
Prognostic value of transbronchial lung cryobiopsy for the multidisciplinary diagnosis of idiopathic pulmonary fibrosis: a retrospective validation study	41
Astegolimab, an anti-ST2, in chronic obstructive pulmonary disease (COPD-ST2OP): a phase 2a, placebo-controlled trial	41
Fourth dose of COVID-19 vaccines in Israel	41
SARS-CoV-2 infection and vaccine effectiveness in England (REACT-1): a series of cross-sectional random community surveys	41
Endoscopic sinus surgery with medical therapy versus medical therapy for chronic rhinosinusitis with nasal polyps: a multicentre, randomised, controlled trial	41
Lung recruitment before surfactant administration in extremely preterm neonates with respiratory distress syndrome (IN-REC-SUR-E): a randomised, unblinded, controlled trial	40
The changing demographics of COVID-19	39
The right place for IL-1 inhibition in COVID-19	39
Proteomic biomarkers of progressive fibrosing interstitial lung disease: a multicentre cohort analysis	39
Increased cardiovascular mortality in African Americans with COVID-19	39